首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >Injection with corticosteroids (ultrasound guided) in patients with an ulnar neuropathy at the elbow, feasibility study
【24h】

Injection with corticosteroids (ultrasound guided) in patients with an ulnar neuropathy at the elbow, feasibility study

机译:肘部尺神经病患者注射皮质类固醇激素(超声引导下),可行性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction and purpose: Unlike carpal tunnel syndrome, little is known about injection with corticosteroids in patients with an ulnar neuropathy at the elbow (UNE). The purpose of this feasibility study is to see whether injection with corticosteroids is safe in patients with UNE and whether there are grounds to launch a prospective placebo-controlled study on the effects of corticosteroids. Methods: Patients with clinical symptoms of UNE and a nerve conduction study compatible with UNE or thickened ulnar nerve at the elbow (10mm2) by ultrasonography were included. All included patients received an ultrasound-guided injection of 1ml containing 40mg methylprednisoloneacetate and 10mg lidocainhydrochloride (Depo-Medrol?). Complications of the injection were monitored. After 3months, nerve conduction studies and ultrasonography were repeated and a clinical outcome determined. Results: Eight patients with nine UNE were included. None of the patients mentioned increase in the symptoms directly after the injection nor had an infection on the injection site or haematoma. After 3months, there was improvement of the symptoms in five patients. One patient deteriorated and three had no change of the symptoms at all. Overall, there was no significant change of the thickness of the ulnar nerve with mean difference -0.056mm2 (95% CI -2.56 to 2.45mm2). Conclusion: We showed that injection with corticosteroids in patients with UNE is easy and safe, and based on this result, we found enough arguments to launch a prospective, placebo-controlled trial to explore the effectiveness of corticosteroids in patients with UNE.
机译:简介和目的:与腕管综合症不同,对于肘部尺神经病患者(UNE)注射皮质类固醇激素知之甚少。这项可行性研究的目的是,观察注射类固醇激素对UNE患者是否安全,以及是否有理由开展前瞻性安慰剂对照研究,以研究皮质类固醇激素的疗效。方法:纳入具有UNE临床症状的患者,并通过超声检查进行与UNE相容的神经传导研究或肘部尺神经增厚(> 10mm2)。所有纳入的患者均接受了1ml的超声引导注射,其中包含40mg泼尼松龙乙酸甲酯和10mg盐酸利多卡因(Depo-Medrol?)。监测注射的并发症。 3个月后,重复进行神经传导研究和超声检查,并确定临床结局。结果:包括8名9名UNE患者。没有患者提到注射后症状立即增加,注射部位或血肿也没有感染。 3个月后,有5例患者的症状得到改善。一名病人恶化,三名症状完全没有改变。总体而言,尺神经厚度无明显变化,平均差为-0.056mm2(95%CI -2.56至2.45mm2)。结论:我们证明了在UNE患者中注射皮质类固醇是容易和安全的,基于这一结果,我们发现了足够的理由来开展一项前瞻性,安慰剂对照试验,以探讨皮质类固醇在UNE患者中的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号